TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The present research aims at examining the effectiveness of a specific set of therapist relational interventions and attitudes, called the Motive-Oriented Therapeutic Relationship (MOTR), based on Plan Analysis (Caspar, 2007) in the early-phase treatment of patients diagnosed with Borderline Personality Disorder.

The investigators intend to include N = 80 outpatients diagnosed with Borderline Personality Disorder, consulting at the Outpatient Personality Disorder Program of the Karl Jaspers Clinical Unit, in collaboration with the Institute of Psychotherapy, at the Department of Psychiatry-CHUV, University of Lausanne and in collaboration with the University of Berne, Switzerland. Patients are assigned by chance to two treatment conditions 1) Control condition (General Psychiatric Management; Gunderson \& Links, 2008) and 2) MOTR-condition. The investigators hypothesize better results in the MOTR-condition, as compared to the control condition in terms of symptom reduction pre-post.

The conduct of the study represents a significant contribution to the understanding and enhancement of relationship aspects in the treatment of patients diagnosed with Borderline Personality Disorder which may be of potential benefit for these patients.


Options:
A: Arm Label: Informational Sessions; Type: SHAM_COMPARATOR; Interventions: Behavioral: Informational sessions describing BPD characteristics | Arm Label: Condensed-DBT treatment intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Condensed-DBT treatment intervention | Intervention Type: BEHAVIORAL; Name: Informational sessions describing BPD characteristics; Assigned to Arm(s): Informational Sessions | Intervention Type: BEHAVIORAL; Name: Condensed-DBT treatment intervention; Assigned to Arm(s): Condensed-DBT treatment intervention
B: Arm Label: General Psychiatric Management (GPM; Gunderson & Links, 2008); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychiatric Management | Arm Label: GPM plus Motive-Oriented Therapeutic Relationship; Type: EXPERIMENTAL; Interventions: Behavioral: Psychiatric Management, Behavioral: Motive-oriented therapeutic relationship/Plan Analysis | Intervention Type: BEHAVIORAL; Name: Psychiatric Management; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship, General Psychiatric Management (GPM; Gunderson & Links, 2008) | Intervention Type: BEHAVIORAL; Name: Motive-oriented therapeutic relationship/Plan Analysis; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship
C: Arm Label: Cognitive Analytic Informed Brief Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive analytic informed brief therapy | Arm Label: Treatment As Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive analytic informed brief therapy; Assigned to Arm(s): Cognitive Analytic Informed Brief Therapy
D: Intervention Type: DRUG; Name: Depakote ER; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy & Safety
Brief Summary: The purpose of this study is to determine whether fecal microbiota transplantation (FMT) is safe and efficacious in the treatment of chronic active ulcerative colitis (UC) by conducting a randomised controlled trial


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Sargramostim (Leukine) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sargramostim (Leukine); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
B: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: ciprofloxacin | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ciprofloxacin; Assigned to Arm(s): 2
D: Arm Label: FMT infusions; Type: ACTIVE_COMPARATOR; Interventions: Biological: FMT infusions | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo infusion | Intervention Type: BIOLOGICAL; Name: FMT infusions; Assigned to Arm(s): FMT infusions | Intervention Type: OTHER; Name: Placebo infusion; Assigned to Arm(s): Placebo arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy & Safety
Brief Summary: The purpose of this study is to determine whether fecal microbiota transplantation (FMT) is safe and efficacious in the treatment of chronic active ulcerative colitis (UC) by conducting a randomised controlled trial


Options:
A: Arm Label: Colonoscopy; Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Arm Label: Nasogastric Tube (NGT); Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Intervention Type: DRUG; Name: Fecal Microbiota Transplant (FMT); Assigned to Arm(s): Colonoscopy, Nasogastric Tube (NGT)
B: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT
C: Arm Label: co-transplantation of FMT and pectin; Type: EXPERIMENTAL; Interventions: Other: co-transplantation of FMT and pectin | Arm Label: single fecal microbiota transplantation; Type: ACTIVE_COMPARATOR; Interventions: Other: single fecal microbiota transplantation | Arm Label: give pectin 20g/d; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: pure give pectin 20g/d for five days | Intervention Type: OTHER; Name: co-transplantation of FMT and pectin; Assigned to Arm(s): co-transplantation of FMT and pectin | Intervention Type: OTHER; Name: single fecal microbiota transplantation; Assigned to Arm(s): single fecal microbiota transplantation | Intervention Type: DIETARY_SUPPLEMENT; Name: pure give pectin 20g/d for five days; Assigned to Arm(s): give pectin 20g/d
D: Arm Label: FMT infusions; Type: ACTIVE_COMPARATOR; Interventions: Biological: FMT infusions | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo infusion | Intervention Type: BIOLOGICAL; Name: FMT infusions; Assigned to Arm(s): FMT infusions | Intervention Type: OTHER; Name: Placebo infusion; Assigned to Arm(s): Placebo arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy & Safety
Brief Summary: The purpose of this study is to determine whether fecal microbiota transplantation (FMT) is safe and efficacious in the treatment of chronic active ulcerative colitis (UC) by conducting a randomised controlled trial


Options:
A: Arm Label: Colonoscopy; Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Arm Label: Nasogastric Tube (NGT); Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Intervention Type: DRUG; Name: Fecal Microbiota Transplant (FMT); Assigned to Arm(s): Colonoscopy, Nasogastric Tube (NGT)
B: Arm Label: FMT infusions; Type: ACTIVE_COMPARATOR; Interventions: Biological: FMT infusions | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo infusion | Intervention Type: BIOLOGICAL; Name: FMT infusions; Assigned to Arm(s): FMT infusions | Intervention Type: OTHER; Name: Placebo infusion; Assigned to Arm(s): Placebo arm
C: Arm Label: faecal transplantation; donor faeces; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment with faecal transplantation (donor faeces) | Arm Label: faecal transplantation; placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: treatment with faecal transplantation (own faeces) | Intervention Type: OTHER; Name: treatment with faecal transplantation (donor faeces); Assigned to Arm(s): faecal transplantation; donor faeces | Intervention Type: OTHER; Name: treatment with faecal transplantation (own faeces); Assigned to Arm(s): faecal transplantation; placebo
D: Arm Label: faecal microbiota filtrate; Type: EXPERIMENTAL; Interventions: Drug: encapsulated faecal microbiota filtrate | Arm Label: faecal microbiota; Type: ACTIVE_COMPARATOR; Interventions: Drug: encapsulated faecal microbiota | Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: encapsulated faecal microbiota filtrate; Assigned to Arm(s): faecal microbiota filtrate | Intervention Type: DRUG; Name: encapsulated faecal microbiota; Assigned to Arm(s): faecal microbiota | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.
Brief Summary: The aim of this study is to look at the effects of Aerobic Exercise (AE) on daily and neurocognitive functioning including memory, attention, the ability to plan activities, and learn new information. Participants will be assigned by chance to receive regular care or exercise sessions in addition to regular care. This study will allow determining the potential positive influence of AE on cognitive and daily functioning in individuals with schizophrenia.


Options:
A: Arm Label: Aerobic Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise | Arm Label: Standard Psychiatric Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Psychiatric Treatment | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise; Assigned to Arm(s): Aerobic Exercise | Intervention Type: OTHER; Name: Standard Psychiatric Treatment; Assigned to Arm(s): Standard Psychiatric Treatment
B: Arm Label: Experimental Treatment; Type: EXPERIMENTAL; Interventions: Other: Computerized plasticity-based adaptive cognitive training | Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available computerized training | Intervention Type: OTHER; Name: Computerized plasticity-based adaptive cognitive training; Assigned to Arm(s): Experimental Treatment | Intervention Type: OTHER; Name: Commercially available computerized training; Assigned to Arm(s): Active Comparator
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computer games | Arm Label: Active; Type: EXPERIMENTAL; Interventions: Behavioral: Neuroadaptive cognitive training | Arm Label: Healthy Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Neuroadaptive cognitive training | Intervention Type: BEHAVIORAL; Name: Neuroadaptive cognitive training; Assigned to Arm(s): Active, Healthy Control | Intervention Type: BEHAVIORAL; Name: Computer games; Assigned to Arm(s): Control
D: Arm Label: Cognitive Remediation; Type: EXPERIMENTAL; Interventions: Drug: Cognitive Remediation | Arm Label: Cognitive activity control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cognitive Remediation; Assigned to Arm(s): Cognitive Remediation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Brief Summary: This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study to evaluate the pharmacokinetics, safety, and tolerability of lumacaftor in combination with ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the F508del-mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.


Options:
A: Arm Label: Lumacaftor/Ivacaftor (LUM/IVA); Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor, Drug: Ivacaftor | Intervention Type: DRUG; Name: Lumacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA) | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA)
B: Arm Label: VX-661/Ivacaftor combination; Type: EXPERIMENTAL; Interventions: Drug: VX-661/Ivacaftor, Drug: Ivacaftor, Drug: Placebo matched to Ivacaftor | Arm Label: Ivacaftor monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo matched to VX-661/ ivacaftor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to VX-661/ ivacaftor, Drug: Placebo matched to Ivacaftor | Intervention Type: DRUG; Name: VX-661/Ivacaftor; Assigned to Arm(s): VX-661/Ivacaftor combination | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor monotherapy, VX-661/Ivacaftor combination | Intervention Type: DRUG; Name: Placebo matched to VX-661/ ivacaftor; Assigned to Arm(s): Ivacaftor monotherapy, Placebo | Intervention Type: DRUG; Name: Placebo matched to Ivacaftor; Assigned to Arm(s): Placebo, VX-661/Ivacaftor combination
C: Arm Label: Ataluren (PTC124®); Type: EXPERIMENTAL; Interventions: Drug: Ataluren (PTC124®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren (PTC124®); Assigned to Arm(s): Ataluren (PTC124®) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Brief Summary: This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study to evaluate the pharmacokinetics, safety, and tolerability of lumacaftor in combination with ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the F508del-mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.


Options:
A: Arm Label: PTC124 PO; Type: EXPERIMENTAL; Interventions: Drug: PTC124 | Intervention Type: DRUG; Name: PTC124; Assigned to Arm(s): PTC124 PO
B: Arm Label: Placebo; Type: OTHER; Interventions: Drug: Placebo | Arm Label: TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: TEZ/IVA, Drug: IVA, Drug: Placebo | Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: IVA, Drug: Placebo | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Ivacaftor, TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ivacaftor, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, TEZ/IVA
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: Lumacaftor/Ivacaftor (LUM/IVA); Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor, Drug: Ivacaftor | Intervention Type: DRUG; Name: Lumacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA) | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of an Intervention of Urban Training in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomised Controlled Trial
Brief Summary: This project plans on a training intervention by using public spaces and urban walkable trails, adapted to each patient needs and capabilities. Primary objective is to assess 12 months effectiveness of the intervention with respect to: (primary outcome): physical activity level, and (secondary outcomes): COPD admissions, exercise capacity, body composition, quality of life, and mental health.


Options:
A: Arm Label: E-Cylinder; Type: ACTIVE_COMPARATOR; Interventions: Device: E-Cylinder | Arm Label: Lightweight Cylinder; Type: ACTIVE_COMPARATOR; Interventions: Device: Lightweight Cylinder | Intervention Type: DEVICE; Name: E-Cylinder; Assigned to Arm(s): E-Cylinder | Intervention Type: DEVICE; Name: Lightweight Cylinder; Assigned to Arm(s): Lightweight Cylinder
B: Arm Label: tiotropium + olodaterol; Type: EXPERIMENTAL; Interventions: Drug: tiotropium, Drug: olodaterol | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium
C: Arm Label: Urban training Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Urban training | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Urban training; Assigned to Arm(s): Urban training Intervention
D: Arm Label: Aclidinium bromide; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of an Intervention of Urban Training in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomised Controlled Trial
Brief Summary: This project plans on a training intervention by using public spaces and urban walkable trails, adapted to each patient needs and capabilities. Primary objective is to assess 12 months effectiveness of the intervention with respect to: (primary outcome): physical activity level, and (secondary outcomes): COPD admissions, exercise capacity, body composition, quality of life, and mental health.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Introductory Disease Education | Intervention Type: OTHER; Name: Introductory Disease Education; Assigned to Arm(s): Education Intervention
B: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A
C: Arm Label: Urban training Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Urban training | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Urban training; Assigned to Arm(s): Urban training Intervention
D: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: care at initiative of the patient (usual GP care) | Arm Label: monitoring controls; Type: EXPERIMENTAL; Interventions: Behavioral: regular practice nurse review (monitoring controls) | Arm Label: self-management; Type: EXPERIMENTAL; Interventions: Behavioral: an integrated self-management education program | Intervention Type: BEHAVIORAL; Name: an integrated self-management education program; Assigned to Arm(s): self-management | Intervention Type: BEHAVIORAL; Name: regular practice nurse review (monitoring controls); Assigned to Arm(s): monitoring controls | Intervention Type: BEHAVIORAL; Name: care at initiative of the patient (usual GP care); Assigned to Arm(s): usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of an Intervention of Urban Training in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomised Controlled Trial
Brief Summary: This project plans on a training intervention by using public spaces and urban walkable trails, adapted to each patient needs and capabilities. Primary objective is to assess 12 months effectiveness of the intervention with respect to: (primary outcome): physical activity level, and (secondary outcomes): COPD admissions, exercise capacity, body composition, quality of life, and mental health.


Options:
A: Arm Label: Telemedicine (TeleRR); Type: EXPERIMENTAL; Interventions: Device: Telemedicine: Maintenance Respiratory Rehabilitation | Arm Label: Clinical Practice (Recommendation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine: Maintenance Respiratory Rehabilitation; Assigned to Arm(s): Telemedicine (TeleRR)
B: Arm Label: Urban training Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Urban training | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Urban training; Assigned to Arm(s): Urban training Intervention
C: Arm Label: COPD, Telehealth; Type: EXPERIMENTAL; Interventions: Device: Telehealth | Arm Label: COPD, Normal clinical practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telehealth; Assigned to Arm(s): COPD, Telehealth
D: Arm Label: Group A, Telerehabilitation; Type: EXPERIMENTAL; Interventions: Other: Telerehabilitation | Arm Label: Group B, Hospital based Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Hospital based Rehabilitation | Arm Label: Group C, Usual care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telerehabilitation; Assigned to Arm(s): Group A, Telerehabilitation | Intervention Type: OTHER; Name: Hospital based Rehabilitation; Assigned to Arm(s): Group B, Hospital based Rehabilitation

Answer: B